Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Real-world testing practices, treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer : a retrospective chart review study (REFLECT)
Authors:ID Janžič, Urška, Klinika Golnik (Author)
ID Turnšek, Nina, Onkološki inštitut (Author)
ID Dediu, Mircea (Author)
ID Shterev Donev, Ivan (Author)
ID Lupu, Roxana (Author)
ID Teodorescu, Gabriela (Author)
ID Ciuleanu, Tudor (Author)
ID Płużański, Adam (Author)
Files:URL URL - Source URL, visit https://www.mdpi.com/1718-7729/29/8/460/pdf?version=1660898466
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Logo OI - Institute of Oncology
Abstract:The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored EGFR/T790M testing and treatment patterns in EGFRm NSCLC patients receiving first- or second-generation (1G/2G) EGFR TKIs as front-line (1L) in eight countries. Pooled data from Central Eastern Europe (CEE) countries from this study (Bulgaria, Poland, Romania, Slovenia) are presented here. This physician-led chart review study was conducted in patients with confirmed-EGFRm NSCLC initiating 1L 1G/2G EGFR TKIs between 2015–2018. The CEE cohort included 389 patients receiving 1L erlotinib (37%), afatinib (34%), and gefitinib (29%). Overall, 320 (82%) patients discontinued 1L, and 298 (77%) progression events were registered. Median progression free survival on 1L TKIs was 14.0 (95% CI: 12.6–15.6) months. Median overall survival from 1L start was 26.6 (95% CI: 24.1–29.0) months. Attrition rate between 1L and next line was 30%. Among patients with 1L progression, 200 (67%) were tested for T790M and 58% were positive. This first CEE analysis of treatments and outcomes in EGFRm NSCLC patients highlights the importance of using the most efficacious therapies currently available in 1L to reduce attrition and improve patient outcomes.
Keywords:lung neoplasms, non-small cell lung carcinoma, Eastern Europe, real-world study, REFLECT study, epidermal growth factor receptor, lung cancer
Geographic coverage:Europe, Eastern; Vzhodna Evropa;
Publication status:Published
Publication version:Version of Record
Article acceptance date:11.08.2022
Publication date:17.08.2022
Place of publishing:Švica
Publisher:MDPI
Year of publishing:2022
Number of pages:str. 5833-5845
Numbering:Vol. 29, iss. 8
PID:20.500.12556/DiRROS-15465 New window
UDC:616.2
ISSN on article:1198-0052
DOI:10.3390/curroncol29080460 New window
COBISS.SI-ID:119484931 New window
Copyright:© 2022 by the authors
Note:Soavtorica iz Slovenije: Nina Turnšek
Publication date in DiRROS:09.09.2022
Views:1070
Downloads:476
Metadata:XML DC-XML DC-RDF
:
JANŽIČ, Urška, TURNŠEK, Nina, DEDIU, Mircea, SHTEREV DONEV, Ivan, LUPU, Roxana, TEODORESCU, Gabriela, CIULEANU, Tudor and PŁUŻAŃSKI, Adam, 2022, Real-world testing practices, treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer : a retrospective chart review study (REFLECT). Current oncology [online]. 2022. Vol. 29, no. 8, p. 5833–5845. [Accessed 23 March 2025]. DOI 10.3390/curroncol29080460. Retrieved from: https://www.mdpi.com/1718-7729/29/8/460/pdf?version=1660898466
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Current oncology
Shortened title:Curr. oncol.
Publisher:Multimed
ISSN:1198-0052
COBISS.SI-ID:1321749 New window

Document is financed by a project

Funder:Other - Other funder or multiple funders
Project number:NCT04031898

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:17.08.2022

Secondary language

Language:Slovenian
Title:Real-world testing practices, treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer: a retrospective chart review study (REFLECT)
Keywords:pljučni rak, pljučne novotvorbe, nedrobnocelični karcinom pljuč, Vzhodna Evropa, klinične študije, raziskava REFLECT, receptor epidermalnega rastnega faktorja, rak pljuč


Back